undamentalytics Newsletter
Sign in

Autolus Therapeutics plc income statement

In fiscal 2025, Autolus Therapeutics plc reported revenue of $75.4m, up 644.9% on the year before, operating income of −$271m (a -358.9% margin) and net income of −$288m, or −$1.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Sept 20162017Sept 20172018Sept 20182019Dec 20192023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue121321075117
Cost of revenue————0119699
Gross profit————2−1−2118
Research and development101636105130138118113
Selling, general and administrative————47102132153
General and administrative592339————
Operating income—−23−58−146−180−241−271−247
Interest expense———04593742
Income before tax−14−23−52−139−208−219−286−279
Income tax−2−4−7−15−0221
Net income−13−20−45−124−208−221−288−280
Diluted EPS−$0.32−$0.36−$0.35−$0.72−$1.20−$0.86−$1.08−$1.05
Diluted shares (average)40m55m126m172m174m255m266m266m
EBITDA—−22−56−141−173−234−262−239

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AUTL vs RCUSAUTL vs SPRYAUTL vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Autolus Therapeutics plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Autolus Therapeutics plc.